Focal Segmental Glomerulosclerosis Market Report 2026

The focal segmental glomerulosclerosis market size has grown strongly in recent years. It will grow from $1.57 billion in 2025 to $1.69 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to proteinuria prevalence, chronic kidney disease burden, corticosteroid usage, nephrology clinic expansion, dialysis infrastructure growth.

The focal segmental glomerulosclerosis market size is expected to see strong growth in the next few years. It will grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to precision nephrology, early disease biomarkers, biologic drug development, transplant program expansion, rare kidney disease funding. Major trends in the forecast period include increased focus on targeted immunosuppressive therapy, rising adoption of combination drug regimens, expansion of early diagnostic screening, growing use of renin-angiotensin system inhibitors, increased kidney transplant preparedness.

The rising prevalence of kidney diseases is expected to propel the growth of the focal segmental glomerulosclerosis (FSGS) market in the coming years. Kidney diseases refer to conditions that impair the structure and function of the kidneys, affecting their ability to filter waste, balance fluids, and regulate essential body functions. The increasing prevalence of kidney diseases is primarily driven by diabetes, as prolonged high blood sugar levels damage the kidneys’ filtering units, leading to diabetic nephropathy. FSGS highlights progressive scarring of the kidney filters, serving as a critical indicator and target for understanding, diagnosing, and managing chronic kidney diseases. For instance, in August 2025, according to the American Kidney Fund, a U.S.-based nonprofit organization, 35.5 million Americans are living with chronic kidney disease (CKD), approximately 815,000 Americans are living with kidney failure, and nearly 555,000 Americans are on dialysis. Therefore, the rising prevalence of kidney diseases is driving the growth of the FSGS market.

Major companies operating in the FSGS market are focusing on developing innovative therapies such as non-immunosuppressive oral medications to improve patient outcomes while reducing treatment-related side effects. Non-immunosuppressive oral medications are drugs taken orally that treat disease without weakening the immune system, targeting kidney damage directly while avoiding immune-related complications. For instance, in May 2025, Travere Therapeutics Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), granting traditional approval for the treatment of FSGS. FILSPARI is a first-in-class therapy that simultaneously blocks both the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual mechanism significantly reduces proteinuria in conditions such as FSGS and IgA nephropathy, offering improved kidney protection while maintaining a strong safety profile compared to existing treatments.

In August 2023, Novartis AG, a Switzerland-based pharmaceutical corporation, acquired Chinook Therapeutics Inc. for $3.5 billion. This acquisition strengthens Novartis’s position in rare kidney diseases by expanding its innovative pipeline with late-stage therapies for IgA nephropathy. Chinook Therapeutics Inc. is a US-based biotechnology company actively developing therapies for FSGS.

Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.

North America was the largest region in the focal segmental glomerulosclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the focal segmental glomerulosclerosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the focal segmental glomerulosclerosis market by increasing costs of immunosuppressants, diagnostic kits, and dialysis-related medical supplies. Drug therapy and kidney transplant support segments are most affected, especially in North America and Asia-Pacific where pharmaceutical and medical device imports are high. Hospitals and specialty clinics experience cost pressure. However, tariffs are supporting domestic production of renal drugs and medical equipment.

The focal segmental glomerulosclerosis market research report is one of a series of new reports that provides focal segmental glomerulosclerosis market statistics, including focal segmental glomerulosclerosis industry global market size, regional shares, competitors with a focal segmental glomerulosclerosis market share, detailed focal segmental glomerulosclerosis market segments, market trends and opportunities, and any further data you may need to thrive in the focal segmental glomerulosclerosis industry. This focal segmental glomerulosclerosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring (sclerosis) in segments of some glomeruli, the kidney’s filtering units, leading to proteinuria and progressive kidney damage. It is significant in clinical diagnosis and research for understanding proteinuria-related kidney diseases and developing therapies to prevent kidney failure.

The main types of FSGS are primary and secondary focal segmental glomerulosclerosis. Primary FSGS involves scarring in scattered regions of some glomeruli, causing proteinuria and gradual loss of kidney function without an identifiable secondary cause. Treatments include drug therapy, dialysis, kidney transplantation, and others, with commonly used drug classes such as immunosuppressants, angiotensin inhibitors, and corticosteroids. These medications are administered orally or parenterally and are used across various settings, including hospitals, homecare, specialty clinics, and others.

The focal segmental glomerulosclerosis market consists of revenues earned by entities by providing services such as diagnostic testing, dialysis services, kidney transplant services, supportive care services, and medical imaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The focal segmental glomerulosclerosis market also includes sales of calcineurin inhibitors, mycophenolate mofetil, rituximab, sparsentan, and diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.